Polyrizon Ltd

PLRZHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 3:59 PM ET

11.02+0.09 (0.80%)

2026-11-12 05:11 CET

Market cap

26.13 USD m

Revenue, TTM

0.00 USD m

Net income, TTM

-4.58 USD m

Free cash flow, TTM

-4.67 USD m

EPS diluted, TTM

-2.75

P/E

Compare

Price

PLRZ against its 20, 50 and 200-day averages

2050200

39.5% under the 52-week high of 18.20 on 4 Dec 2025. 52-week low 2.88 on 26 Nov 2025. Last 15 sessions, 47.3% high to low

Volume 0.17× normal · the line is the 50-bar volume average

Profile

PLRZ

52-week range, 53% of the way up

2.8818.20

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Employees	6
IPO	Oct 29, 2024
Beta	-1.10
ATR, 14d	0.90
Rel volume	0.17
Short float	2.56%
Insider own	0.59%
Inst own	9.31%

Snapshot

6 groups

Valuation

Index	-
Market Cap	26.14M
Enterprise Value	11.09M
Income	-4.58M
Sales	0.00M
Book/sh	11.49
Cash/sh	6.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Oct 29, 2024

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.96
P/C	1.74
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	36.37
Current Ratio	36.37
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

Earnings

EPS (ttm)	-2.75
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	80.47% 39.74%
Sales past 3/5Y	- -
EPS Y/Y TTM	99.20%
Sales Y/Y TTM	-
EPS Q/Q	-6.93%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Ownership

Insider Own	0.59%
Insider Trans	0.00%
Inst Own	9.31%
Inst Trans	-3.01%
ROA	-21.02%
ROE	-21.42%
ROIC	-18.77%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	9.72%
SMA50	6.47%
SMA200	-11.60%
Trades	-

Technical

Shs Outstand	2.37M
Shs Float	2.36M
Short Float	2.56%
Short Ratio	1.25
Short Interest	0.06M
52W High	18.20 -39.47%
52W Low	2.88 282.54%
Volatility	7.83% 9.01%
ATR (14)	0.90
RSI (14)	57.38
Beta	-1.10
Rel Volume	0.17
Avg Volume	48.37K
Volume	8,088

Performance

Perf Week	-0.97%
Perf Month	13.11%
Perf Quarter	2.48%
Perf Half Y	-27.42%
Perf YTD	29.77%
Perf Year	115.74%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	10.93
Price	11.02
Change %	0.80%

Peers

Mkt cap

Ticker	Company	Mkt cap
MIST	Milestone Pharmaceuticals Inc	82.44M
VTGN	Vistagen Therapeutics Inc	8.34M
IMRN	Immuron Limited ADR	7.48M
PULM	Pulmatrix Inc	4.78M
OKYO	OKYO Pharma Limited	74.52M
SCNI	Scinai Immunotherapeutics Ltd ADR	0.69M
TLSA	Tiziana Life Sciences Ltd	79.68M
CANF	Can-Fite Biopharma Ltd ADR	4.71M
SPRC	SciSparc Ltd	0.82M
XTLB	X.T.L. Biopharmaceuticals Ltd ADR	7.44M

Ticker

Company

Mkt cap

MIST

Milestone Pharmaceuticals Inc

82.44M

VTGN

Vistagen Therapeutics Inc

8.34M

IMRN

Immuron Limited ADR

7.48M

PULM

Pulmatrix Inc

4.78M

OKYO

OKYO Pharma Limited

74.52M

SCNI

Scinai Immunotherapeutics Ltd ADR

0.69M

TLSA

Tiziana Life Sciences Ltd

79.68M

CANF

Can-Fite Biopharma Ltd ADR

4.71M

SPRC

SciSparc Ltd

0.82M

XTLB

X.T.L. Biopharmaceuticals Ltd ADR

7.44M

Insider trading

6 filings

Insider	Relationship	Date	Transaction	Cost	Shares	Value	Total held	Form
Izraeli Tomer	Chief Executive Officer	Mar 31 '26	Sale	11.85	500	5,925	31,512	Apr 01 04:15 PM
Carmel Liron	Director	Mar 31 '26	Sale	12.36	942	11,643	3,127	Apr 01 04:15 PM
Adler Oz	Director	Mar 31 '26	Sale	12.05	3,292	39,669	19,850	Apr 01 04:15 PM
Carmel Liron	Director	Mar 30 '26	Sale	11.00	100	1,100	4,069	Mar 31 04:17 PM
Izraeli Tomer	Chief Executive Officer	Mar 30 '26	Sale	10.90	3,900	42,510	32,012	Mar 31 04:17 PM
Turgeman Tidhar	Chief Technology Officer	Mar 30 '26	Sale	10.90	2,917	31,795	17,518	Mar 31 04:16 PM

News

latest 14 of 160

Nov-09-26 04:01PMPOLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN (GlobeNewswire)
Oct-27-26 08:16AMPolyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker (GlobeNewswire)
Oct-05-26 07:32AMPolyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform (GlobeNewswire)
Sep-22-26 08:33AMPolyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker (GlobeNewswire)
Sep-04-26 11:58AMPolyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement (GlobeNewswire) -10.51%
Sep-03-26 08:50AMPolyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement (GlobeNewswire)
Sep-02-26 07:32AMPolyrizon Completes All Five U.S. Site Contracts for NASARIX First-in-Human Allergy Study (GlobeNewswire) -12.88%
Aug-20-26 09:30AMPolyrizon Completes Clinical Site Network for NASARIX Study and Advances Toward Patient Enrollment (GlobeNewswire) -6.26%
Jul-02-26 08:29AMPolyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) (InvestorsHub) +8.83%
07:32AMPolyrizon Announces Successful Results for NASARIX Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial (GlobeNewswire)
Jun-29-26 08:44AMPolyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial (GlobeNewswire) +11.06%
Jun-17-26 08:15AMPolyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform (GlobeNewswire) +15.55%
Jun-15-26 08:05AMPolyrizon Advances NASARIX Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway (GlobeNewswire)
Jun-10-26 07:47AMPolyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology (GlobeNewswire)

Key figures

Revenue, TTM	0.00
Net income, TTM	-4.58
EPS diluted, TTM	-2.75
EBIT, TTM	-8.09
Free cash flow, TTM	-4.67
Gross margin	-%
Operating margin	-%
Net margin	-%
Market cap	26.13
P/E	-
Sales Y/Y, TTM	-

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
No quarterly earnings.

Period

Reported

EPS act

EPS est

EPS rep

Sales act

Sales est

Analysts

No quarterly earnings.

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
No annual earnings.

Period

EPS act

EPS est

EPS rep

Sales act

Sales est

No annual earnings.

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
No estimate revisions.

Period

Type

Date

Estimates

Down

Mean

Low

High

No estimate revisions.

Estimate history

Period	2019	2020	2021	2022	2023	2024	2025
EPS, annual	0	-26.1	-254.265	-278.58	-214.575	-552.51	-2.074
EPS, quarterly
Period
Sales, annual	0	0	0	0	0	0	0
Period	2019	2020	2021	2022	2023	2024	2025
Sales, quarterly
Period
Shares, annual	0.003	0.003	0.003	0.003	0.003	0.003	1.608
Period	2019	2020	2021	2022	2023	2024	2025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.31	0.34	0.12	0.00	0.01	0.01	0.00	0.00
Gross Profit	-0.31	-0.34	-0.12	-0.00	-0.01	-0.01	-0.00	0.00
Selling, General and Administrative Excl. Other	7.78	5.91	1.18	0.63	0.89	0.70	0.07	0.00
Research and Development	2.74	2.13	0.53	0.33	0.35	0.25	0.04	0.00
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-8.09	-6.25	-1.30	-0.64	-0.90	-0.70	-0.07	0.00
Interest Expense	0.01	3.14	0.00	0.00	0.00	0.00	0.00	0.00
Unusual Expense	-2.92	-5.55	0.24	-0.05	-0.14	0.00	0.00	0.00
Net Income Before Taxes	-4.58	-3.34	-1.55	-0.60	-0.78	-0.71	-0.07	0.00
Income Taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Consolidated Net Income	-4.58	-3.34	-1.55	-0.60	-0.78	-0.71	-0.07	0.00
Net Income From Continuing Operations	-4.58	-3.34	-1.55	-0.60	-0.78	-0.71	-0.07	0.00
Net Income	-4.58	-3.34	-1.55	-0.60	-0.78	-0.71	-0.07	0.00
EPS (Recurring)	-3.66	-4.49	-491.44	-226.59	-314.63	-254.26	-26.11	0.00
EPS (Basic, Before Extraordinaries)	-2.75	-2.07	-552.51	-214.57	-278.58	-254.26	-26.10	0.00
EPS (Diluted)	-2.75	-2.07	-552.51	-214.57	-278.58	-254.26	-26.10	0.00
EBITDA	-7.78	-5.91	-1.18	-0.63	-0.89	-0.70	-0.07	0.00
Non-Operating Income (Expense)	0.59	0.51	0.00	-0.01	-0.03	-0.01	-0.00	0.00
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	2.63	1.31	0.05	0.10	0.13	0.18	0.00	0.00
Shares Outstanding	2.13	1.61	0.00	0.00	0.00	0.00	0.00	0.00
Market Capitalization	26.13	26.13	13,160.71	13,100.07	-	-	-	-

Income statement, quarterly

Currency USD, millions
Metric	2026S1	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1	2022S2
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.15	0.15	0.19	0.12	0.00	0.00	0.00	0.00
Gross Profit	-0.15	-0.15	-0.19	-0.12	-0.00	-0.00	-0.00	-0.00
Selling, General and Administrative Excl. Other	4.17	3.61	2.30	0.84	0.35	0.31	0.32	0.32
Research and Development	1.38	1.36	0.78	0.40	0.14	0.16	0.17	0.10
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-4.32	-3.76	-2.48	-0.95	-0.35	-0.31	-0.33	-0.32
Interest Expense	0.00	0.00	3.14	0.00	0.24	0.10	-	-
Unusual Expense	-2.59	-0.33	-5.22	0.00	0.00	0.00	0.00	0.00
Net Income Before Taxes	-1.42	-3.16	-0.18	-0.96	-0.59	-0.41	-0.19	-0.19
Income Taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Consolidated Net Income	-1.42	-3.16	-0.18	-0.96	-0.59	-0.41	-0.19	-0.19
Net Income From Continuing Operations	-1.42	-3.16	-0.18	-0.96	-0.59	-0.41	-0.19	-0.19
Net Income	-1.42	-3.16	-0.18	-0.96	-0.59	-0.41	-0.19	-0.19
EPS (Recurring)	-1.79	-2.11	-15.92	-342.24	-210.28	-146.26	-68.30	-66.87
EPS (Basic, Before Extraordinaries)	-0.79	-1.96	-0.74	-342.24	-210.28	-146.26	-68.31	-66.87
EPS (Diluted)	-0.79	-1.96	-0.74	-342.24	-210.28	-146.26	-68.31	-66.87
EBITDA	-4.17	-3.61	-2.30	-0.84	-0.35	-0.31	-0.32	-0.32
Non-Operating Income (Expense)	0.31	0.28	0.23	0.00	0.00	0.00	0.13	0.14
Stock Option Compensation Expense	1.72	0.91	0.40	0.02	0.03	0.08	0.02	0.04
Shares Outstanding	2.13	1.61	0.98	0.00	0.00	0.00	0.00	0.00
Market Capitalization	26.13	13.53	30.17	13,160.71	13,100.07	-	-	-

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY
Cash & Short Term Investments	12.27	2.55	0.04	0.04	0.52	0.01	0.00
Short Term Receivables	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.59	0.10	0.01	0.01	0.02	0.01	0.00
Total Current Assets	12.86	2.65	0.05	0.05	0.54	0.02	0.00
Net Property, Plant & Equipment	0.01	0.01	0.01	0.02	0.02	0.01	0.00
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Intangible Assets	2.55	2.88	0.00	0.00	0.00	0.00	0.00
Other Assets	6.02	0.00	0.49	0.48	0.12	0.00	0.00
Total Assets	21.44	5.55	0.56	0.55	0.69	0.02	0.00
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Liabilities	0.44	0.26	0.50	1.20	0.69	0.01	0.00
Total Current Liabilities	0.44	0.26	0.50	1.20	0.69	0.01	0.00
Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	0.44	0.26	0.50	1.20	0.69	0.01	0.00
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.25	0.25	0.25	0.25	0.25
Common Equity	20.99	5.29	-0.19	-0.90	-0.25	-0.23	-0.25
Total Shareholders Equity	20.99	5.29	0.06	-0.65	-0.00	0.02	0.00
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	20.99	5.29	0.06	-0.65	-0.00	0.02	0.00
Total Liabilities & Stockholders Equity	21.44	5.55	0.56	0.55	0.69	0.02	0.00
Book Value Per Share	13.05	1,890.36	-68.30	-321.85	-89.76	-82.97	-88.69
Tangible Book Value Per Share	11.47	858.99	-68.30	-321.85	-89.76	-82.97	-88.69
Full-Time Employees	6	6	-	-	-	-	-
Price to Book Ratio	0.96	-506,220.84	-503,888.02	-	-	-	-
Return on Assets	-24.72	-50.61	-108.60	-126.36	-200.00	-608.33	-
Return on Equity	-25.38	-57.83	-	-	-10,938.46	-912.50	-
Return on Invested Capital	-15.89	-29.23	-1,052.63	-	-	-456.25	-
Quick Ratio	29.03	10.16	0.11	0.04	0.79	2.38	-
Current Ratio	29.03	10.16	0.11	0.04	0.79	2.38	-

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY
Net Income	-4.58	-3.34	-1.55	-0.60	-0.78	-0.71	-0.07	0.00
Depreciation	0.31	0.34	0.12	0.00	0.01	0.01	0.00	0.00
Other Funds (Non Cash)	-0.48	-1.38	0.30	0.05	-0.01	0.18	0.00	-
Funds from Operations	-4.76	-4.37	-1.13	-0.54	-0.79	-0.52	-0.07	0.00
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	0.09	-0.16	-0.02	0.01	-0.34	0.03	-0.00	0.00
Cash from Operating Activities	-4.66	-4.53	-1.15	-0.54	-1.13	-0.49	-0.07	0.00
Capital Expenditures	-6.01	-6.01	0.00	0.00	-0.00	-0.02	-0.01	0.00
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	-4.07	-10.00	0.03	0.00	0.00	0.00	0.00	0.00
Purchase of Investments	-11.07	-10.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	7.00	0.00	0.03	0.00	0.00	0.00	0.00	0.00
Other Uses	-0.53	-0.53	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	-10.60	-16.53	0.03	0.00	-0.00	-0.02	-0.01	0.00
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	7.85	19.81	3.67	0.51	0.65	1.02	0.09	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	7.85	19.81	3.67	0.51	0.65	1.02	0.09	0.00
Proceedsfrom Stock Options	0.00	0.00	3.67	0.26	0.00	1.02	0.09	0.00
Issuance or Reduction of Debt, Net	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Financing Activities	7.85	19.81	3.67	0.51	0.65	1.02	0.09	0.00
Net Change in Cash	-7.42	-1.25	2.55	-0.03	-0.49	0.51	0.01	0.00
Free Cash Flow	-4.67	-4.54	-1.15	-0.54	-1.14	-0.51	-0.08	0.00
Preferred Dividends (Cash Flow)	-	0.00	0.00	-	-	-	-	-
Deferred Taxes & Investment Tax Credit	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Balance sheet, quarterly

Currency USD, millions
Metric	2026S1	2025S2	2025S1	2024S2	2024S1	2023S2
Cash & Short Term Investments	15.05	12.27	15.83	2.55	0.02	0.04
Short Term Receivables	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	1.25	0.59	0.20	0.10	0.02	0.01
Total Current Assets	16.29	12.86	16.03	2.65	0.04	0.05
Net Property, Plant & Equipment	0.01	0.01	0.01	0.01	0.01	0.01
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00
Intangible Assets	2.40	2.55	2.70	2.88	0.00	0.00
Other Assets	6.16	6.02	0.00	0.00	0.53	0.49
Total Assets	24.86	21.44	18.74	5.55	0.59	0.56
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00	0.00	0.00	0.15	0.00
Accounts Payable	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Liabilities	0.45	0.44	0.36	0.26	0.21	0.50
Total Current Liabilities	0.45	0.44	0.36	0.26	0.36	0.50
Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	0.45	0.44	0.36	0.26	0.36	0.50
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.25	0.25
Common Equity	24.41	20.99	18.38	5.29	-0.03	-0.19
Total Shareholders Equity	24.41	20.99	18.38	5.29	0.22	0.06
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	24.41	20.99	18.38	5.29	0.22	0.06
Total Liabilities & Stockholders Equity	24.86	21.44	18.74	5.55	0.59	0.56
Book Value Per Share	11.49	13.05	18.75	1,890.36	-9.30	-68.30
Tangible Book Value Per Share	10.36	11.47	16.00	858.99	-9.30	-68.30
Price to Book Ratio	0.96	0.45	3.52	-506,220.84	-503,888.02	-
Return on Assets	-21.02	-24.72	-11.74	-50.61	-	-108.60
Return on Equity	-21.42	-25.38	-12.20	-57.83	-	-
Return on Invested Capital	-5.83	-15.04	-0.96	-18.10	-264.86	-717.54
Quick Ratio	36.37	29.03	44.04	10.16	0.12	0.11
Current Ratio	36.37	29.03	44.04	10.16	0.12	0.11

Cash flow, quarterly

Currency USD, millions
Metric	2026S1	2025S2	2025S1	2024S2	2024S1	2023S2
Net Income	-1.42	-3.16	-0.18	-0.96	-0.59	-0.41
Depreciation	0.15	0.15	0.19	0.12	0.00	0.00
Other Funds (Non Cash)	-0.86	0.38	-1.76	0.02	0.28	0.17
Funds from Operations	-2.13	-2.62	-1.75	-0.82	-0.31	-0.24
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	0.18	-0.09	-0.07	0.01	-0.03	0.04
Cash from Operating Activities	-1.96	-2.71	-1.82	-0.81	-0.34	-0.20
Capital Expenditures	-0.00	-6.01	-0.00	0.00	0.00	0.00
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	5.93	-10.00	0.00	0.03	0.00	0.00
Purchase of Investments	-1.07	-10.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	7.00	0.00	0.00	0.03	0.00	0.00
Other Uses	0.00	-0.53	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	5.93	-16.53	-0.00	0.03	0.00	0.00
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00	0.00	-
Change in Capital Stock	3.13	4.72	15.10	3.47	0.21	0.39
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	3.13	4.72	15.10	3.47	0.21	0.39
Proceedsfrom Stock Options	0.00	0.00	0.00	3.47	0.21	0.14
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	-0.16	0.15	-0.20
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Financing Activities	3.13	4.72	15.10	3.31	0.36	0.19
Net Change in Cash	7.10	-14.52	13.27	2.53	0.02	-0.02
Free Cash Flow	-1.96	-2.71	-1.82	-0.81	-0.34	-0.20

Revenue breakdown

Revenue split	-

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	2.56%	0.1M	2.4M	53.50K
2026-10-15	2.90%	0.1M	2.4M	60.68K
2026-09-30	2.15%	0.1M	2.4M	64.19K
2026-09-15	2.35%	0.1M	2.4M	67.14K
2026-08-31	2.90%	0.1M	2.4M	53.12K
2026-08-14	4.55%	0.1M	2.1M	46.56K
2026-07-31	3.06%	0.1M	2.1M	44.01K
2026-07-15	2.40%	0.0M	2.1M	45.73K
2026-06-30	1.95%	0.0M	2.1M	44.95K
2026-06-15	2.67%	0.0M	1.8M	41.74K
2026-05-29	1.72%	0.0M	1.8M	42.91K
2026-05-15	2.14%	0.0M	1.8M	42.91K
2026-04-30	2.00%	0.0M	1.8M	51.93K
2026-04-15	3.80%	0.1M	1.8M	51.61K
2026-03-31	2.66%	0.0M	1.3M	82.78K
2026-03-13	3.03%	0.0M	1.3M	97.18K
2026-02-27	3.29%	0.0M	1.3M	3.17M
2026-02-13	4.20%	0.1M	1.3M	3.17M
2026-01-30	4.01%	0.1M	1.3M	3.16M
2026-01-15	9.38%	0.1M	1.3M	3.10M

Option chain

expiry 2026-11-11

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-11-09	8-A12B			SEC
2026-11-09	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-11-09	SEC
2026-10-27	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-10-27	SEC
2026-10-07	S-8	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans		SEC
2026-10-05	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-10-05	SEC
2026-10-01	EFFECT	Effectiveness filing by commission order		SEC
2026-09-28	F-1/A			SEC
2026-09-28	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-30	SEC
2026-09-18	F-1	Registration statement for certain foreign private issuers		SEC
2026-09-10	D	Notice of sales of securities on Form D (Regulation D)		SEC
2026-09-04	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-09-04	SEC
2026-09-04	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-09-04	SEC
2026-09-04	424B5			SEC
2026-08-20	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-08-20	SEC
2026-08-14	SCHEDULE 13G/A			SEC
2026-07-13	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-13	SEC
2026-07-02	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-02	SEC
2026-06-29	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-29	SEC
2026-06-17	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-17	SEC
2026-06-15	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-15	SEC
2026-06-10	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-10	SEC
2026-06-08	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-08	SEC
2026-06-08	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-08	SEC
2026-06-05	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-05	SEC
2026-05-27	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-05-27	SEC
2026-05-13	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-05-13	SEC
2026-05-04	EFFECT	Effectiveness filing by commission order		SEC
2026-05-04	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-05-04	SEC
2026-04-30	CORRESP			SEC
2026-04-30	F-1/A			SEC

Filed

Form

Description

Period

Link

2026-11-09

8-A12B

Month	Sold	Sells
2026-11	0	0
2026-10	0	0
2026-09	0	0
2026-08	0	0
2026-07	0	0
2026-06	0	0
2026-05	0	0
2026-04	0	0
2026-03	132.64K	6
2026-02	0	0
2026-01	0	0
2025-12	0	0
2025-11	0	0

Manager	% owned
MMCAP International Inc. SPC	9.57%
HRT FINANCIAL LP	1.03%
Caitong International Asset Management Co., Ltd	0.00%
MORGAN STANLEY	0.00%
CITIGROUP INC	0.00%

Fund	% owned
Putnam Global Income Trust	16.83%
INTERNATIONAL CORE EQUITY 2 PORTFOLIO	1.09%
Dimensional World ex. U.S. Core Equity 2 ETF	0.69%
The Canadian Small Company Series	0.65%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF	0.56%
World ex U.S. Core Equity Portfolio	0.18%
Dimensional International Small Cap ETF	0.16%
DFA INTERNATIONAL SMALL CAP VALUE PORTFOLIO	0.12%
International Social Core Equity Portfolio	0.11%
International Vector Equity Portfolio	0.10%